Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Atossa Genetics Inc

Healthcare US ATOS

2.46USD
-0.125(4.84%)

Last update at 2026-06-12T20:14:00Z

Day Range

2.452.70
LowHigh

52 Week Range

3.7619.35
LowHigh

Fundamentals

  • Previous Close 2.58
  • Market Cap49.69M
  • Volume638963
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-37.12500M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-3.78

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -34.77000M -25.50400M -30.09400M -26.96000M -20.60600M
Minority interest - - - - -
Net income -34.77000M -25.50400M -30.09400M -26.22900M -20.60600M
Selling general administrative 15.96M 13.50M 14.04M 12.61M 11.31M
Selling and marketing expenses - - 14.01M - -
Gross profit -0.01600M -0.01700M -0.02300M - -
Reconciled depreciation 0.02M 0.02M 0.01M 0.00800M 0.02M
Ebit -37.14100M -27.62100M -31.37700M -27.69900M -20.52100M
Ebitda -37.12500M -27.60400M -31.35400M -27.69100M -20.49800M
Depreciation and amortization 0.02M 0.02M 0.02M 0.00800M 0.02M
Non operating income net other - - - 0.73M -0.08500M
Operating income -37.14100M -27.62100M -31.37700M -27.69100M -20.52100M
Other operating expenses 37.14M 27.62M 31.38M 27.69M 20.52M
Interest expense - - - -0.00800M 0.09M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 2.38M 4.05M 3.78M 0.88M -
Net interest income 2.38M 4.05M 3.78M 0.88M -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - -0.73100M 0.09M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 37.14M 27.62M 31.38M 27.69M 20.52M
Cost of revenue 0.02M 0.02M 0.02M - -
Total other income expense net 2.37M 2.12M 1.28M 0.73M -0.08500M
Discontinued operations - - - - -
Net income from continuing ops -34.77000M -25.50400M -29.83100M -26.96000M -20.60600M
Net income applicable to common shares - - - -26.96000M -20.60600M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 47.61M 76.44M 96.25M 123.53M 141.26M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 4.32M 3.37M 3.65M 2.42M 1.19M
Total liab 8.26M 4.97M 5.24M 5.57M 3.13M
Total stockholder equity 39.35M 71.48M 91.02M 117.96M 138.14M
Deferred long term liab - - - - -
Other current liab 3.96M 4.29M 4.43M 2.60M 1.41M
Common stock 1.55M 23.49M 22.79M 22.79M 22.79M
Capital stock 1.55M 23.49M - 22.79M 22.79M
Retained earnings -246.56200M -211.79200M -186.28800M -156.19400M -129.23400M
Other liab - - - - -
Good will - - - - -
Other assets - - - 0.64M 0.00200M
Cash 41.30M 71.08M 88.57M 110.89M 136.38M
Cash and equivalents - - - - -
Total current liabilities 8.26M 4.97M 5.24M 5.57M 3.13M
Current deferred revenue - - - - -
Net debt -41.29900M -71.08400M -88.57000M -110.89000M -136.37700M
Short term debt - - - - -
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity 284.37M 259.78M 254.51M 250.78M 244.58M
Property plant equipment - - - - 0.02M
Total current assets 45.62M 74.46M 92.22M 118.20M 141.24M
Long term investments - 0.00000M - 4.70M -
Net tangible assets - - - 117.96M 137.55M
Short term investments - - - - -
Net receivables - - -0.00149M 0.74M 1.07M
Long term debt - - - - -
Inventory - - 1.49M 4.14M 2.60M
Accounts payable 4.29M 0.68M 0.81M 2.96M 1.72M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - 0.00000M - -0.58200M
Additional paid in capital - - - - -
Common stock total equity - - - 22.79M 22.79M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -156.19400M -129.23400M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.99M 1.99M 2.32M 0.64M 0.00200M
Deferred long term asset charges - - - - -
Non current assets total 1.99M 1.99M 4.03M 5.33M 0.02M
Capital lease obligations - - - - 0.00000M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.01900M -2.02200M -4.72700M -0.00900M
Change to liabilities - - - 2.44M 0.13M
Total cashflows from investing activities -0.02300M -0.01900M -0.01400M -4.72700M -0.00900M
Net borrowings - - - - -
Total cash from financing activities 0.00000M 3.67M -1.47500M 0.00000M 113.30M
Change to operating activities - - - -1.84700M -1.28400M
Net income -34.77000M -25.50400M -30.09400M -26.96000M -20.60600M
Change in cash -29.78500M -17.37600M -22.43000M -25.48700M 96.82M
Begin period cash flow 71.19M 88.57M 111.00M 136.49M 39.66M
End period cash flow 41.41M 71.19M 88.57M 111.00M 136.49M
Total cash from operating activities -29.76200M -21.03000M -20.94100M -20.76000M -16.47200M
Issuance of capital stock - - - 0.00000M 69.67M
Depreciation 0.02M 0.02M 0.02M 0.00800M 0.02M
Other cashflows from investing activities - - -0.01399M -4.70000M -
Dividends paid - - - - -
Change to inventory -0.98300M -0.61100M 2.54M - -
Change to account receivables - - 0.74M - -
Sale purchase of stock - 0.00000M -1.47500M - 44.21M
Other cashflows from financing activities - 3.67M -1.47352M -4.72700M 43.64M
Change to netincome - - - 6.79M 5.27M
Capital expenditures 0.02M 0.02M 0.01M 0.03M 0.00900M
Change receivables - - - - -
Cash flows other operating - - - -3.04100M -1.63200M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -25.48700M 96.82M
Change in working capital 2.35M 0.45M 1.52M -0.59900M -1.15600M
Stock based compensation 2.65M 2.29M 4.62M 6.79M 5.27M
Other non cash items 2.35M 1.72M 2.99M 0.00300M 26.96M
Free cash flow -29.78500M -21.04900M -20.95500M -20.78700M -16.48100M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ATOS
Atossa Genetics Inc		 -0.125 4.84% 2.46 - 7.04 1872.06 1.35 3287.25 2.01
NVO
Novo Nordisk A/S		 -0.08 0.18% 43.88 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.99 4.74% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.115 0.03% 444.93 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 0.66 0.11% 612.14 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.

Atossa Genetics Inc

107 Spring Street, Seattle, WA, United States, 98104

Key Executives

Name Title Year Born
Dr. Steven C. Quay FCAP, M.D., Ph.D. Chairman, CEO & Pres 1951
Mr. Kyle Guse CPA, Esq., CPA CFO, Gen. Counsel & Sec. 1964
Ms. Heather Rees VP of Fin. & Accounting NA
Ms. Delly Behen P.H.R. VP of Admin. & HR NA
Ms. Janet Rose Rea MSPH, RAC Sr. VP of Regulatory, Quality & Clinical Affairs NA
Dr. Richard Graydon M.D., Ph.D. Interim Chief Medical Officer NA
Dr. Steven C. Quay FCAP, M.D., Ph.D. Chairman, CEO & President 1951
Ms. Heather Rees CPA Senior VP of Finance & Principal Accounting Officer 1973
Ms. Delly Behen P.H.R. Senior Vice President of Administration & HR NA
Mr. Eric Van Zanten Vice President of Investor & Public Relations NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.